The more you look at aducanumab, both the dubious FDA approval and the thin odds that it will perform medically, the less there is to like.
Read more...Whistleblowers charge that Trump-style doctoring of scientific reports is continuing under Biden.
Read more...Intel is the poster child of how stock buybacks come at the cost of technological innovation.
Read more...OPEC is squabbling again. Will the factions settle their hash?
Read more...Falling mortgage applications and rising home inventories signal a coming housing market pullback.
Read more...Probling why more people arent interested in having children.
Read more...Another big and costly dustup over Chinese listings in the US. But now Chinese officials signal they want broad-scale change.
Read more...Yves here. We’re doing a bit of catchup by featuring some significant stories that were still crowded out a bit due to the competing news plus the Fourth of July tuneout. One is on the super dodgy approval of the big ticket, very dubious effectiveness Alzheimer’s drug Aducanumab. And “big ticket” is no understatement; the […]
Read more...How do the rich intend to carry on as general conditions deteriorate?
Read more...Varoufakis describes techno-feudalism and speculates on where it is going.
Read more...Offensive military strategies and deliberate use of disproportionate violence against civilians are a core part of Israel policies
Read more...The Covid infection rates in the UK, despite higher vaccination rates than America, are a danger in and of itself and a warning to the US.
Read more...An informant publicly recanting critically important testimony against Julian Assange seems unlikely to change the trajectory of his trial.
Read more...Covid and other major political challenges show that devising policies isn’t the hard part: it’s getting the public to go along.
Read more...Some great songs lurk in what is normally the B side netherworld. Your picks?
Read more...